Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PCVX 
Vaxcyte Inc (PCVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: PCVX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $106.33
1 Year Target Price $106.33
| 9 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.81% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.18B USD | Price to earnings Ratio - | 1Y Target Price 106.33 |
Price to earnings Ratio - | 1Y Target Price 106.33 | ||
Volume (30-day avg) 10 | Beta 1.04 | 52 Weeks Range 27.66 - 121.06 | Updated Date 09/15/2025 |
52 Weeks Range 27.66 - 121.06 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.44% | Return on Equity (TTM) -21.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2600835330 | Price to Sales(TTM) - |
Enterprise Value 2600835330 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -14.43 | Shares Outstanding 129823000 | Shares Floating 116843616 |
Shares Outstanding 129823000 | Shares Floating 116843616 | ||
Percent Insiders 0.65 | Percent Institutions 114.93 |
Upturn AI SWOT
Vaxcyte Inc
Company Overview
History and Background
Vaxcyte, Inc. (PCVX) is a clinical-stage vaccine innovation company revolutionizing vaccine design and development to deliver differentiated and novel vaccines to improve global health. Founded in 2013, Vaxcyte aims to address the limitations of current vaccines and develop more effective and broader protection against infectious diseases.
Core Business Areas
- Vaccine Development: Focuses on developing novel and improved vaccines against prevalent and deadly diseases.
- Cell-Free Protein Synthesis (CFPS) Platform: Utilizes a proprietary CFPS technology to create complex proteins required for vaccine development, allowing for rapid development and efficient production of vaccines.
Leadership and Structure
Grant Pickering is the CEO. The organizational structure consists of research and development, clinical operations, manufacturing, and commercial teams.
Top Products and Market Share
Key Offerings
- Vax-24: A 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to improve upon existing PCVs by offering broader serotype coverage and enhanced immune responses. Competitors include Pfizer (Prevnar 20) and Merck (V116).
- Vax-A1: A vaccine candidate targeting Group A Streptococcus (Strep A) infections, a significant global health burden. Competitors include multiple companies in early-stage development.
Market Dynamics
Industry Overview
The vaccine market is a large and growing market driven by increasing awareness of the benefits of vaccination, government initiatives to promote vaccination, and the emergence of new infectious diseases.
Positioning
Vaxcyte is positioned as an innovator in the vaccine space, leveraging its CFPS technology to develop differentiated and improved vaccines that address unmet needs.
Total Addressable Market (TAM)
The total addressable market for pneumococcal vaccines is estimated to be in the billions of dollars annually. Vaxcyte aims to capture a significant portion of this market with its Vax-24 candidate. The Group A Streptococcus TAM is also substantial.
Upturn SWOT Analysis
Strengths
- Proprietary CFPS technology platform
- Strong pipeline of vaccine candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Clinical-stage company with no currently approved products
- High R&D costs
- Dependence on successful clinical trial outcomes
- Relatively small company compared to established players
Opportunities
- Expanding into new vaccine targets
- Partnering with larger pharmaceutical companies
- Securing regulatory approvals for vaccine candidates
- Addressing global health needs through vaccine development
Threats
- Clinical trial failures
- Competition from established vaccine manufacturers
- Regulatory hurdles
- Changes in vaccine guidelines
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GSK
Competitive Landscape
Vaxcyte differentiates itself through its CFPS technology, aiming to develop more effective and broader vaccines. However, it faces stiff competition from established players with significant resources and market share.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of pipeline development and expansion of clinical programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of vaccine candidates. Analyst estimates vary depending on the perceived probability of success for the pipeline.
Recent Initiatives: Recent initiatives include advancing Vax-24 into Phase 3 trials and progressing Vax-A1 through Phase 1/2 clinical studies.
Summary
Vaxcyte is a clinical-stage company with a promising vaccine pipeline built on its proprietary CFPS technology. While the company has no revenue-generating products yet, the success of its lead candidate, Vax-24, could significantly impact its valuation. Investors should monitor clinical trial results and competitor activity closely. Its innovative technology is a strength, but commercial success is not guaranteed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vaxcyte Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2020-06-12 | Co-Founder, CEO & Director Mr. Grant E. Pickering M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 414 | Website https://vaxcyte.com |
Full time employees 414 | Website https://vaxcyte.com | ||
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.